Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Free Access

MRI Assessment of Ischemic Lesion Evolution within White and Gray Matter

Berner L.-P.a, d · Cho T.-H.b, d · Haesebaert J.c · Bouvier J.a, d · Wiart M.a, d · Hjort N.f · Klærke Mikkelsen I.f · Derex L.b, d · Thomalla G.g · Pedraza S.h · Østergaard L.f · Baron J.-C.e, i · Nighoghossian N.b, d · Berthezène Y.a, d

Author affiliations

aDepartment of Neuroradiology, bDepartment of Stroke Medicine, and cPôle Information Médicale Evaluation Recherche, Hospices Civils de Lyon, dCREATIS, CNRS UMR 5220-INSERM U1044, Université Lyon 1 INSA-Lyon, Lyon, and eINSERM U894, Université Paris Descartes, Sorbonne Paris Cité, France; fCenter of Functionally Integrative Neuroscience, Århus University, Aarhus, Denmark; gKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; hDepartment of Radiology (IDI), Girona Biomedical Research Institute (IDIBGI), Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain; iDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Corresponding Author

Prof. Yves Berthezène, MD, PhD

Service de Neuroradiologie

Hôpital Neurologique Pierre Wertheimer - Hospices Civils de Lyon

59 Boulevard Pinel, FR-69677 Bron Cedex (France)

E-Mail yves.berthezene@chu-lyon.fr

Related Articles for ""

Cerebrovasc Dis 2016;41:291-297

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: In acute ischemic stroke (AIS), gray matter (GM) and white matter (WM) have different vulnerabilities to ischemia. Thus, we compared the evolution of ischemic lesions within WM and GM using MRI. Methods: From a European multicenter prospective database (I-KNOW), available T1-weighted images were identified for 50 patients presenting with an anterior AIS and a perfusion weighted imaging (PWI)/diffusion weighted imaging (DWI) mismatch ratio of 1.2 or more. Six lesion compartments were outlined: initial DWI (b = 1,000 s/mm2) lesion, initial PWI-DWI mismatch (Tmax >4 s and DWI-negative), final infarct mapped on 1-month fluid-attenuated inversion recovery (FLAIR) imaging, lesion growth between acute DWI and 1-month FLAIR, DWI lesion reversal at 1 month and salvaged mismatch. The WM and GM were segmented on T1-weighted images, and all images were co-registered within subjects to the baseline MRI. WM and GM proportions were calculated for each compartment. Results: Fifty patients were eligible for the study. Median delay between symptom onset and baseline MRI was 140 min. The percentage of WM was significantly greater in the following compartments: initial mismatch (52.5 vs. 47.5%, p = 0.003), final infarct (56.7 vs. 43.3%, p < 0.001) and lesion growth (58.9 vs. 41.2%, p < 0.001). No significant difference was found between GM and WM percentages within the initial DWI lesion, DWI reversal and salvaged mismatch compartments. Conclusions: Ischemic lesions may extend preferentially within the WM. Specific therapeutic strategies targeting WM ischemic processes may deserve further investigation.

© 2016 S. Karger AG, Basel


References

  1. Bristow MS, Simon JE, Brown RA, Eliasziw M, Hill MD, Coutts SB, Frayne R, Demchuk AM, Mitchell JR: MR perfusion and diffusion in acute ischemic stroke: human gray and white matter have different thresholds for infarction. J Cereb Blood Flow Metab 2005;25:1280-1287.
  2. Simon JE, Bristow MS, Lu H, Lauzon ML, Brown RA, Manjón JV, Eliasziw M, Frayne R, Buchan AM, Demchuk AM, Mitchell JR; Calgary Stroke Program: A novel method to derive separate gray and white matter cerebral blood flow measures from MR imaging of acute ischemic stroke patients. J Cereb Blood Flow Metab 2005;25:1236-1243.
  3. Arakawa S, Wright PM, Koga M, Phan TG, Reutens DC, Lim I, Gunawan MR, Ma H, Perera N, Ly J, Zavala J, Fitt G, Donnan GA: Ischemic thresholds for gray and white matter: a diffusion and perfusion magnetic resonance study. Stroke 2006;37:1211-1216.
  4. Falcao AL, Reutens DC, Markus R, Koga M, Read SJ, Tochon-Danguy H, Sachinidis J, Howells DW, Donnan GA: The resistance to ischemia of white and gray matter after stroke. Ann Neurol 2004;56:695-701.
  5. Tisserand M, Malherbe C, Turc G, Legrand L, Edjlali M, Labeyrie MA, Seners P, Mas JL, Méder JF, Baron JC, Oppenheim C: Is white matter more prone to diffusion lesion reversal after thrombolysis? Stroke 2014;45:1167-1169.
  6. Koga M, Reutens DC, Wright P, Phan T, Markus R, Pedreira B, Fitt G, Lim I, Donnan GA: The existence and evolution of diffusion-perfusion mismatched tissue in white and gray matter after acute stroke. Stroke 2005;36:2132-2137.
  7. Alawneh JA, Jones PS, Mikkelsen IK, Cho TH, Siemonsen S, Mouridsen K, Ribe L, Morris RS, Hjort N, Antoun N, Gillard JH, Fiehler J, Nighoghossian N, Warburton EA, Østergaard L, Baron JC: Infarction of ‘non-core-non-penumbral' tissue after stroke: multivariate modelling of clinical impact. Brain 2011;134(pt 6):1765-1776.
  8. Carrera E, Jones PS, Alawneh JA, Klærke Mikkelsen I, Cho TH, Siemonsen S, Guadagno JV, Mouridsen K, Ribe L, Hjort N, Fryer TD, Carpenter TA, Aigbirhio FI, Fiehler J, Nighoghossian N, Warburton EA, Ostergaard L, Baron JC: Predicting infarction within the diffusion-weighted imaging lesion: does the mean transit time have added value? Stroke 2011;42:1602-1607.
  9. Hermitte L, Cho TH, Ozenne B, Nighoghossian N, Mikkelsen IK, Ribe L, Baron JC, Østergaard L, Derex L, Hjort N, Fiehler J, Pedraza S, Hermier M, Maucort-Boulch D, Berthezène Y: Very low cerebral blood volume predicts parenchymal hematoma in acute ischemic stroke. Stroke 2013;44:2318-2320.
  10. Cheng B, Forkert ND, Zavaglia M, Hilgetag CC, Golsari A, Siemonsen S, Fiehler J, Pedraza S, Puig J, Cho TH, Alawneh J, Baron JC, Ostergaard L, Gerloff C, Thomalla G: Influence of stroke infarct location on functional outcome measured by the modified Rankin scale. Stroke 2014;45:1695-1702.
  11. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET Investigators: Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
  12. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP; DEFUSE Investigators: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
  13. Ogata T, Christensen S, Nagakane Y, Ma H, Campbell BC, Churilov L, Lansberg MG, Straka M, De Silva DA, Mlynash M, Bammer R, Olivot JM, Desmond PM, Albers GW, Davis SM, Donnan GA; EPITHET and DEFUSE Investigators: The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study. Stroke 2013;44:87-93.
  14. Campbell BC, Macrae IM: Translational perspectives on perfusion-diffusion mismatch in ischemic stroke. Int J Stroke 2013;10:153-162.
  15. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR: High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726-736.
  16. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, Bammer R, Marks MP, Albers GW: Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009;40:469-475.
  17. Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T; IMS-I Investigators: Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005;36:2400-2403.
  18. Cocosco CA, Zijdenbos AP, Evans AC: A fully automatic and robust brain MRI tissue classification method. Med Image Anal 2003;7:513-527.
  19. Zhang K, Sejnowski TJ: A universal scaling law between gray matter and white matter of cerebral cortex. Proc Natl Acad Sci U S A 2000;97:5621-5626.
  20. Matute C, Domercq M, Pérez-Samartín A, Ransom BR: Protecting white matter from stroke injury. Stroke 2013;44:1204-1211.
  21. Payabvash S, Souza LC, Wang Y, Schaefer PW, Furie KL, Halpern EF, Gonzalez RG, Lev MH: Regional ischemic vulnerability of the brain to hypoperfusion: the need for location specific computed tomography perfusion thresholds in acute stroke patients. Stroke 2011;42:1255-1260.
  22. Baron JC: Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc Dis 1999;9:193-201.
  23. Ho PW, Reutens DC, Phan TG, Wright PM, Markus R, Indra I, Young D, Donnan GA: Is white matter involved in patients entered into typical trials of neuroprotection? Stroke 2005;36:2742-2744.
  24. Dohmen C, Kumura E, Rosner G, Heiss WD, Graf R: Adenosine in relation to calcium homeostasis: comparison between gray and white matter ischemia. J Cereb Blood Flow Metab 2001;21:503-510.
  25. Dewar D, Yam P, Mcculloch J: Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 1999;375:41-50.
  26. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, Moreau G, Goldweber R, Sanossian N; FAST-MAG Investigators and Coordinators: Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med 2015;372:528-536.
  27. Campbell BC, Purushotham A, Christensen S, Desmond PM, Nagakane Y, Parsons MW, Lansberg MG, Mlynash M, Straka M, De Silva DA, Olivot JM, Bammer R, Albers GW, Donnan GA, Davis SM; EPITHET-DEFUSE Investigators: The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab 2012;32:50-56.
  28. Sakamoto Y, Kimura K, Shibazaki K, Inoue T, Uemura J, Aoki J, Sakai K, Iguchi Y: Early ischaemic diffusion lesion reduction in patients treated with intravenous tissue plasminogen activator: infrequent, but significantly associated with recanalization. Int J Stroke 2013;8:321-326.
  29. Nagakane Y, Christensen S, Brekenfeld C, Ma H, Churilov L, Parsons MW, Levi CR, Butcher KS, Peeters A, Barber PA, Bladin CF, De Silva DA, Fink J, Kimber TE, Schultz DW, Muir KW, Tress BM, Desmond PM, Davis SM, Donnan GA; EPITHET Investigators: EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke 2011;42:59-64.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: November 04, 2015
Accepted: January 10, 2016
Published online: February 12, 2016
Issue release date: April 2016

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.